language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform
  1. Home
  2. Therakos Institute

Welcome to the Therakos Institute

TKS Institute TM CMYK 2022

At the Therakos Institute, our primary goal is to advance knowledge and understanding around Extracorporeal Photopheresis (ECP) immunomodulation. We have forged valuable partnerships with leading experts from around the world, regularly bringing our best and brightest together to provide accessible education to HCPs. Through these collaborations, we aim to build a better future for patients.

Gain online access to our live and on-demand webinars.

Sign-up to the upcoming webinars to learn more about the ECP therapy and get the opportunity to watch any past webinars you didn’t have chance to attend.

Register now

or

OUR EDUCATIONAL OFFER

Our Webinars Feature Image

Webinars

Up-to-date coverage of a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Explore our webinars

Symposia V2

Symposia

Major thought leaders present on specific topics on the latest in ECP Immunomodulation – guaranteed to be both stimulating and informative.

Symposia

Centres Excellence V2

Centres of Excellence

We partner with several European Centres of Excellence (CoE) to provide high-quality professional education to committed healthcare professionals.

Centres of Excellence

Speaker Meetings V2

Speaker meetings

The latest scientific knowledge and advancements in ECP brought to life in conversation by major thought leaders.

Speaker Meetings

Rectangle 204 (1)

Ask the Expert

Private, one-to-one sessions with leading experts in their respective fields of relevance to ECP and its clinical applications.

Ask the Expert

Upcoming Events

CoE Course

May 23 - 24, 2023

Interactive Workshop on Treating GvHD

University Medical Center (UKE) and University Heart Center (UHZ), Hamburg, Germany

Discover More
Speaker Meeting

Jun 8 - 9, 2023

French Operator Days
This event is in French

Paris, France

CoE Course

Jun 13 - 14, 2023

Interactive Workshop on Heart Transplant

University Medical Center (UKE) and University Heart Center (UHZ), Hamburg, Germany

Discover More
Webinar

Jun 13, 2023

How to improve overall survival in acute GvHD by applying ECP

CoE Course

Jun 22 - 23, 2023

THERAKOS CELLEX Photopheresis System Practical Course

The Tirol Kliniken, Innsbruck, Austria

Discover More
Speaker Meeting

Jun 22, 2023

Pan-London GvHD Therapeutic Landscape in 2023 and Beyond

London, United Kingdom

Speaker Meeting

Jun 22, 2023

Overcoming the challenges in Solid Organ Transplantation with the Extracorporeal Photopheresis: What’s new?

Dubai, UAE

Symposium

Sep 8, 2023

ADO 2023 Clinical Symposium: Benefits of ECP alone and in combination for the treatment of CTCL patients

Hamburg, Germany

Symposium

Sep 8, 2023

EBMT 2023 8th International Transplant Course: Save the date

Barcelona, Spain

Symposium

Sep 15, 2023

EBMT 2023 TCWP Clinical Symposium: Save the date

Copenhagen, Denmark

Symposium

Sep 18, 2023

ESOT 2023 Clinical Symposium: Role of ECP in the prevention and treatment of rejection post-solid organ transplantation

Athens, Greece

Symposium

Sep 21, 2023

DGTI 2023 Clinical Symposium: Extracorporeal photopheresis: Collection efficiency of ECP systems - Vascular accesses in the ICU

Berlin, Germany

Symposium

Sep 22, 2023

EORTC 2023 Clinical Symposium: Save the date

Leiden, Netherlands

CoE Course

Sep 26 - 27, 2023

Interactive Workshop on Lung Transplant Rejection

Vienna University Hospital, Vienna, Austria

Discover More
CoE Course

Sep 27 - 28, 2023

Interactive Workshop on Dermatological Diseases

Vienna University Hospital, Vienna, Austria

Discover More
CoE Course

Sep 28 - 29, 2023

THERAKOS CELLEX Photopheresis System Practical Course

The Tirol Kliniken, Innsbruck, Austria

Discover More
CoE Course

Oct 10 - 11, 2023

Interactive Workshop on Treating GvHD

University Medical Center (UKE) and University Heart Center (UHZ), Hamburg, Germany

Discover More
Symposium

Oct 19, 2023

COSTEM 2023 Clinical Symposium: Save the date

Berlin, Germany

CoE Course

Oct 30 - 31, 2023

A–Z of Treating Patients with ECP – The Nordic Approach Oct

The Oslo University Hospital, Oslo, Norway

Discover More
Speaker Meeting

Nov 23 - 24, 2023

3rd Therakos “3-Country Meeting”

Vienna, Austria

CoE Course

Nov 30 - Dec 1, 2023

THERAKOS CELLEX Photopheresis System Practical Course 

The Tirol Kliniken, Innsbruck, Austria

Discover More
Rectangle 204 (1) (1)

Developing leadership in healthcare

An SDA Bocconi course.

Sponsored by Mallinckrodt.

Discover More

Rectangle 204 (3)

Brilliant Speakers

Our communication course dedicated to bringing
our leaders into the new era of engagement.

Discover More

Create your

Logomytherakos

account to access everything the Therakos Institute offers

Register now

or

You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?